Reaction
Walking Disability reporting signals
As of the last recalculation, Walking Disability appears in 2,069 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is AMLODIPINE BESYLATE AND VALSARTAN (PRR 11.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Amlodipine Besylate And Valsartan | 13 | 11.9 | 11.9 |
| Alemtuzumab | 21 | 11.0 | 11.0 |
| Rotigotine | 12 | 8.4 | 8.4 |
| Selexipag | 20 | 7.9 | 7.9 |
| Bicalutamide | 11 | 7.3 | 7.3 |
| Teriflunomide | 31 | 7.0 | 7.0 |
| Ocrelizumab | 39 | 6.4 | 6.4 |
| Cenobamate | 5 | 6.0 | 6.0 |
| Siponimod | 5 | 5.6 | 5.7 |
| Macitentan | 37 | 5.5 | 5.5 |
| Rasagiline Mesylate | 6 | 5.4 | 5.4 |
| Rivastigmine | 10 | 5.4 | 5.4 |
| Dalfampridine | 33 | 4.7 | 4.7 |
| Brivaracetam | 4 | 4.5 | 4.5 |
| Ticagrelor | 14 | 4.4 | 4.4 |
| Bosentan | 22 | 4.4 | 4.4 |
| Sunitinib Malate | 16 | 4.1 | 4.1 |
| Asfotase Alfa | 4 | 4.0 | 4.0 |
| Ravulizumab | 5 | 3.7 | 3.7 |
| Botulinum Toxin Type A | 4 | 3.2 | 3.2 |
| Glatiramer Acetate | 17 | 2.9 | 2.9 |
| Alirocumab | 6 | 2.4 | 2.4 |
| Pimavanserin Tartrate | 6 | 1.1 | 1.1 |